Andy

FREDERICK, Md., Jan. 9, 2025 /PRNewswire/ — Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced today that it has entered into an exclusive agreement with Nudge Therapeutics to acquire the company and their preclinical cyclic AMP-GMP (cGAS) inhibitor compounds.  The agreement allows Veralox to continue development of Nudge’s compounds and trigger acquisition of the company upon achievement of downstream milestones. Financial terms were not disclosed.

GERMANTOWN, Md., & VENLO, The Netherlands–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use.

BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers.

Montgomery County, MD — The Montgomery County Economic Development Corporation (MCEDC) announced that Bill Tompkins will step down as President & CEO when his term ends in August 2025. Tompkins has served in this role since August 15, 2022.

“This marks a significant moment for MCEDC,” stated Elana Fine, Chair of the Board of Directors. “We extend our gratitude to Bill for his outstanding leadership over the past six years, as both the Chief Operating Officer and as President & CEO. His dedication has laid a strong foundation for future growth while fostering inclusion, driving collaboration, and ensuring stability during challenging times.”

ROCKVILLE, Md., Jan. 7, 2025 /PRNewswire/ — Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.

David Loose joined Essex Management as a partner in February 2009 and has played a pivotal role in the company’s growth. Starting as Vice President for Business Operations and Development, he later served as Chief Business Officer, overseeing critical operations, driving client-focused innovation, and delivering strategic initiatives such as NCI’s Clinical Trials Reporting Program (CTRP). His leadership and dedication to Essex’s mission have been instrumental in building its reputation as a trusted partner in the biomedical and health technology sectors.

“David’s leadership and dedication to Essex’s mission make him the ideal choice to guide the company forward,” said Sastry Chilukuri, CEO of Emmes Group. “His focus on innovation and client success will ensure Essex continues to deliver transformative solutions in biomedical informatics and health IT.”

The Washington D.C., Maryland, and Virginia (DMV) region has quickly become one of the nation’s top destinations for startups and tech innovation. With over 270,000 tech jobs and $5 billion in venture capital raised in 2023, the DMV stands out as a vibrant and rapidly growing ecosystem.

In a recent LinkedIn post, Christon Hill, Program Manager at Georgetown Tech Ventures (GTV) and the Office of Technology Commercialization (OTC) at Georgetown University, highlights the factors driving this growth. He points to the region’s proximity to federal agencies, cutting-edge research institutions, and a culture of collaboration as key ingredients for success.

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025.

COLLEGE PARK, Md.–(BUSINESS WIRE)– IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the completion of its acquisition of substantially all of the assets of Qubitekk, Inc., a prominent quantum networking company. The acquisition brings Qubitekk’s esteemed team, advanced technology, and extensive patent portfolio into IonQ’s operations, solidifying IonQ’s position at the forefront of quantum networking and computing.

Quantum networks are poised to become important infrastructure, with the potential to drive transformative applications in sectors such as defense, finance, and energy. These networks facilitate highly secure communication between multiple quantum nodes using entangled qubits. The technology also enables precise timing synchronization, a transport layer for quantum sensing, and a backbone for distributed quantum computing. With the development and 2022 launch of the EPB Quantum Network in Chattanooga, Tennessee—the first commercially available quantum network in the U.S.—Qubitekk has established itself as a leader in quantum networking.

ROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today highlighted its strategic outlook for 2025 and a re-prioritization of resources, with a focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting first-line metastatic gastric cancers, with further potential in other solid tumors.